Smartlab Europe

News

Sandoz globally collaborates with Biocon on next generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Under the...

Cmed to showcase own eSource technology at SCOPE 2018

Cmed, an innovative technology-led CRO, will demonstrate the eSource and live data analytics capabilities of encapsia®, a next generation clinical data suite, at Summit for Clinical Operations Executives 2018 this month. Cmed’s encapsia® is a cloud-based...

TraceLink Expands Leadership Team with New Senior Vice President of Engineering and New Chief Technology Officer Appointment

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced two key new senior leadership appointments: John Hogan hired as senior vice president...

CluePoints Wins Best Risk-Based Monitoring Solution in 2018 Biotechnology Awards

CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has been honoured in this year’s Biotechnology Awards with the CluePoints® solution being named the “Best Risk-Based Monitoring Solution”. The...

Data Integrity, Business and Process Efficiencies Take Center Stage as CRF Health Appoints New Vice President of Quality Assurance

CRF Health, a leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, has announced the appointment of former Novartis veteran and eClinical Quality Assurance and Data Integrity Specialist, Tom Haag, as Vice President,...

Sterling Pharma Solutions expands presence in Japan

Global API developer and manufacturer, Sterling Pharma Solutions, has experienced growth in the Japanese market as a result of its technical capabilities and innovation strategy. The contract development and manufacturing organisation (CDMO) now works with a...

MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced completion of a pre-planned interim futility analysis of the Phase 3 SOPHIA trial. This...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »